梅州没有白带但是有异味梅州淋菌性尿道炎咨询,梅州流产手术前要准备什么,梅州月经推迟白带咖啡色,梅州治疗慢性盆腔炎的医院,梅州盆腔炎得症状,梅州怀孕40天人流价格,梅州妇女宫颈炎怎么诊疗

BEIJING, Sept. 2 (Xinhuanet) -- The amount of space junk orbiting the Earth could cause fatal leaks in spaceships or destroy valuable satellites, according to a report released by the U.S. National Research Council.Computer models have shown that the number of orbital debris "has reached a tipping point, with enough currently in orbit to continually collide and create even more debris, raising the risk of spacecraft failures," the Research Council said Thursday.So far, there are 22,000 pieces of debris large enough to track from the ground, but smaller objects could still cause serious damage.New international regulations are needed to limit space junk.And more researches should be done to test the possible use of launching magnetic nets or giant umbrellas to push the debris further towards the Earth where it would burn up, or into a higher but safer orbit.

BEIJING, Aug. 30 (Xinhuanet) -- The United Nations is warning authorities to be on high alert of bird flu as the virus appears to be returning.The UN Food and Agriculture Organization said in a statement Monday a mutant strain is spreading across parts of Asia, and there could be a spill-over to humans.However, it said at this stage, there's no need for any alarm.A mutant strain of H5N1, which can apparently sidestep defenses of existing vaccines, is spreading in China and Vietnam, it said.It said the variant of the virus appears able to side step Vaccines.The UN is concerned the new form of the virus could spread to Cambodia, Thailand and Malaysia, as well as the Korean Peninsula and Japan."Wild birds may introduce the virus, but people's actions in poultry production and marketing spread it," said FAO's chief veterinary office Juan Lubroth in urging greater preparedness and surveillance, according to media reports.Outbreaks of the virus peaked in 2006 before it was eradicated from most countries.

LOS ANGELES, June 4 (Xinhua) -- Pregnant women who eat high-fat diet may be more likely to have a higher rate of stillbirth, a new study suggests.Researchers at Oregon Health & Science University (OHSH) came to the conclusion after observing 24 pregnant Japanese macaques that ate either a diet comprising 32 percent calories from fat or a control diet with 14 percent fat calories for at least four years.The researchers found the monkeys that ate a high-fat diet experienced a significant decrease in blood flow from the uterus to the placenta, a reduction of 38 percent to 56 percent, and a rise in placental inflammation.This was the case regardless of whether the monkeys were obese or slender. The risk of stillbirth was further compounded, however, when the monkeys were obese with hyper-insulinemia, or pre-diabetes.A large order of McDonald's french fries are shown May 22, 2008. McDonald's has switched to cooking oils free of trans fats in all of its restaurants in the United States and Canada, Chief Executive Jim Skinner said on may 23Eating a high-fat diet decreases blood flow from the mother to the placenta, the temporary organ that nourishes the unborn fetus, thus raising the risk of stillbirth, the researchers explained.Because the placental structure of the Japanese macaque is very similar to that in humans, cause and effect can be better established, the researchers said.Additional studies are needed to determine exactly how a high- fat diet decreases placental blood flow, the researchers noted.This is the first study to explain exactly how a fatty diet contributes to stillbirth, the researchers said in the study appearing in the June edition of the journal Endocrinology.The researchers hope their work will inform expectant moms and their physicians about the inherent dangers of a high-calorie, high- fat diet."This study demonstrates that maternal diet during pregnancy has a profound influence on both placental and fetal development," said Antonio Frias, M.D., principal investigator and assistant professor of obstetrics and gynecology (perinatology/maternal-fetal medicine) in the OHSU School of Medicine."The high-calorie, high-fat diet common in our society has negative effects on placental function and may be a significant contributor to adverse pregnancy outcomes, such as stillbirth."Previous studies have shown that nearly all adverse outcomes during pregnancy -- abnormal fetal growth, preeclampsia, preterm labor and stillbirth -- are in some way associated with an abnormally developed, or damaged, placenta, the temporary organ that nourishes the unborn fetus.In addition, maternal obesity has been associated with placental inflammation and dysfunction and an increased risk of stillbirth.Taking these findings into account, the researchers hypothesized that eating a diet high in fat during pregnancy also may increase the risk of placental inflammation and the risk of stillbirth.The researchers said they plan to conduct further studies on the impact of dietary changes and diet supplementation on improving outcomes in both monkeys and humans.

LOS ANGELES, June 4 (Xinhua) -- Pregnant women who eat high-fat diet may be more likely to have a higher rate of stillbirth, a new study suggests.Researchers at Oregon Health & Science University (OHSH) came to the conclusion after observing 24 pregnant Japanese macaques that ate either a diet comprising 32 percent calories from fat or a control diet with 14 percent fat calories for at least four years.The researchers found the monkeys that ate a high-fat diet experienced a significant decrease in blood flow from the uterus to the placenta, a reduction of 38 percent to 56 percent, and a rise in placental inflammation.This was the case regardless of whether the monkeys were obese or slender. The risk of stillbirth was further compounded, however, when the monkeys were obese with hyper-insulinemia, or pre-diabetes.A large order of McDonald's french fries are shown May 22, 2008. McDonald's has switched to cooking oils free of trans fats in all of its restaurants in the United States and Canada, Chief Executive Jim Skinner said on may 23Eating a high-fat diet decreases blood flow from the mother to the placenta, the temporary organ that nourishes the unborn fetus, thus raising the risk of stillbirth, the researchers explained.Because the placental structure of the Japanese macaque is very similar to that in humans, cause and effect can be better established, the researchers said.Additional studies are needed to determine exactly how a high- fat diet decreases placental blood flow, the researchers noted.This is the first study to explain exactly how a fatty diet contributes to stillbirth, the researchers said in the study appearing in the June edition of the journal Endocrinology.The researchers hope their work will inform expectant moms and their physicians about the inherent dangers of a high-calorie, high- fat diet."This study demonstrates that maternal diet during pregnancy has a profound influence on both placental and fetal development," said Antonio Frias, M.D., principal investigator and assistant professor of obstetrics and gynecology (perinatology/maternal-fetal medicine) in the OHSU School of Medicine."The high-calorie, high-fat diet common in our society has negative effects on placental function and may be a significant contributor to adverse pregnancy outcomes, such as stillbirth."Previous studies have shown that nearly all adverse outcomes during pregnancy -- abnormal fetal growth, preeclampsia, preterm labor and stillbirth -- are in some way associated with an abnormally developed, or damaged, placenta, the temporary organ that nourishes the unborn fetus.In addition, maternal obesity has been associated with placental inflammation and dysfunction and an increased risk of stillbirth.Taking these findings into account, the researchers hypothesized that eating a diet high in fat during pregnancy also may increase the risk of placental inflammation and the risk of stillbirth.The researchers said they plan to conduct further studies on the impact of dietary changes and diet supplementation on improving outcomes in both monkeys and humans.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.